RU2569733C2 - Агонисты 5-нт4-рецепторов для лечения деменции - Google Patents

Агонисты 5-нт4-рецепторов для лечения деменции Download PDF

Info

Publication number
RU2569733C2
RU2569733C2 RU2012139034/15A RU2012139034A RU2569733C2 RU 2569733 C2 RU2569733 C2 RU 2569733C2 RU 2012139034/15 A RU2012139034/15 A RU 2012139034/15A RU 2012139034 A RU2012139034 A RU 2012139034A RU 2569733 C2 RU2569733 C2 RU 2569733C2
Authority
RU
Russia
Prior art keywords
methyl
group
piperidin
carboxamide
dementia
Prior art date
Application number
RU2012139034/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2012139034A (ru
Inventor
Хироюки ОХСИРО
Акиеси ФУДЗИЮТИ
Юкинори ТАКЕ
Original Assignee
Раквалиа Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Раквалиа Фарма Инк. filed Critical Раквалиа Фарма Инк.
Publication of RU2012139034A publication Critical patent/RU2012139034A/ru
Application granted granted Critical
Publication of RU2569733C2 publication Critical patent/RU2569733C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2012139034/15A 2010-02-12 2011-02-14 Агонисты 5-нт4-рецепторов для лечения деменции RU2569733C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28243210P 2010-02-12 2010-02-12
US61/282,432 2010-02-12
PCT/JP2011/000793 WO2011099305A1 (en) 2010-02-12 2011-02-14 5-ht4 receptor agonists for the treatment of dementia

Publications (2)

Publication Number Publication Date
RU2012139034A RU2012139034A (ru) 2014-03-20
RU2569733C2 true RU2569733C2 (ru) 2015-11-27

Family

ID=44367591

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012139034/15A RU2569733C2 (ru) 2010-02-12 2011-02-14 Агонисты 5-нт4-рецепторов для лечения деменции

Country Status (11)

Country Link
US (1) US8980922B2 (ko)
EP (1) EP2533780B1 (ko)
JP (1) JP6023926B2 (ko)
KR (1) KR101737388B1 (ko)
CN (2) CN102753172A (ko)
BR (1) BR112012020060B8 (ko)
CA (1) CA2789663C (ko)
ES (1) ES2640752T3 (ko)
MX (1) MX343165B (ko)
RU (1) RU2569733C2 (ko)
WO (1) WO2011099305A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9775843B2 (en) 2012-10-11 2017-10-03 Grünenthal GmbH Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders
US9790211B2 (en) 2013-03-20 2017-10-17 Suven Life Sciences Limited 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
FR3006686A1 (fr) * 2013-06-05 2014-12-12 Univ Caen Composes inhibiteurs de l'acetylcholinesterase et agonistes des recepteurs serotoninergiques 5ht4, a effet promnesiant, leurs procedes de preparation et compositions pharmaceutiques les contenant
JP6161823B2 (ja) 2013-12-16 2017-07-12 スヴェン・ライフ・サイエンシズ・リミテッド ５−ｈｔ４受容体アゴニストとしてのインダゾール化合物
ES2734734T3 (es) 2015-02-13 2019-12-11 Suven Life Sciences Ltd Compuestos de amida como agonistas del receptor 5-HT4
JP6900028B2 (ja) * 2017-03-29 2021-07-07 国立大学法人帯広畜産大学 パーキンソン病に併発した認知障害の治療剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005092882A1 (en) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
WO2007096352A1 (en) * 2006-02-22 2007-08-30 Glaxo Group Limited 5-amino-6-bromo-n-{ [1- (tetrahydr0-2h-pyran-4-ylmethyl) -4-piperidinyl] methyl}-3, 4 -dihydro-2h-chromene-8-carboxamide as 5-ht4 receptor agonist
RU2006133320A (ru) * 2004-02-18 2008-03-27 Тереванс Соединения индазолкарбоксамида в качестве агонистов 5-нт4 рецепторов
RU2008129615A (ru) * 2005-12-22 2010-01-27 Новартис АГ (CH) Комбинация агониста 5-ht4 и ингибитора холинэстеразы

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5864039A (en) 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
EP0873990A1 (en) * 1995-09-22 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and medicinal use thereof
MY134008A (en) 1999-12-22 2007-11-30 Merck Frosst Canada Inc Subtituted 8-arylquinoline phospohodiestrase-4 inhibitors
JP4223287B2 (ja) 2001-01-22 2009-02-12 メモリー・ファーマスーティカルズ・コーポレーション 新規な化合物及び製薬上許容し得るそれらの塩並びにそれらを用いた薬剤組成物
BR0207302A (pt) 2001-02-08 2004-02-10 Memory Pharm Corp Trifluorometilpurinas como inibidores da fosfodiesterase 4
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
BR0314584A (pt) * 2002-09-20 2005-08-09 Pfizer Compostos piperidinil-imidazopiridina n-substituìda como moduladores e receptores 5-ht4
GB0313772D0 (en) 2003-06-13 2003-07-23 Merck Sharp & Dohme Therapeutic treatment
ES2377484T3 (es) * 2003-09-03 2012-03-28 Pfizer, Inc. Compuestos de bencimidazolona que tiene actividad agonista del receptor 5-HT
US7964727B2 (en) 2003-11-24 2011-06-21 Pfizer Inc. Quinolonecarboxylic acid compounds having 5-HT4 receptor agonistic activity
BRPI0507180A (pt) 2004-01-29 2007-06-26 Pfizer derivados de 1-isopropil-2-oxo-1,2-diidropiridina-3-carboxamida tendo atividade agonìstica de receptor 5-ht4
AU2005254800B2 (en) 2004-06-15 2010-12-09 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
JP4129445B2 (ja) * 2004-06-15 2008-08-06 ファイザー・インク ベンズイミダゾロンカルボン酸誘導体
JP2008509088A (ja) * 2004-09-02 2008-03-27 ファイザー株式会社 ベンズイミダゾロンカルボン酸誘導体
ATE513827T1 (de) 2005-02-22 2011-07-15 Pfizer Oxyindol-derivate als 5ht4-rezeptor-agonisten

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006133320A (ru) * 2004-02-18 2008-03-27 Тереванс Соединения индазолкарбоксамида в качестве агонистов 5-нт4 рецепторов
WO2005092882A1 (en) * 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
RU2008129615A (ru) * 2005-12-22 2010-01-27 Новартис АГ (CH) Комбинация агониста 5-ht4 и ингибитора холинэстеразы
WO2007096352A1 (en) * 2006-02-22 2007-08-30 Glaxo Group Limited 5-amino-6-bromo-n-{ [1- (tetrahydr0-2h-pyran-4-ylmethyl) -4-piperidinyl] methyl}-3, 4 -dihydro-2h-chromene-8-carboxamide as 5-ht4 receptor agonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RUSSO O. et al. "Design, synthesis and biological evaluation of new 5-HT4 receptor agonists: application as amiloid cascade modulators and potential therapeutic utility in alzheimer’s disease". J Med Chem 2009, 52, 2214-2225, найдено 13.02.2015, найдено из Интернет: http://libgen.asia/e9192df50bc84ffa6d24be4d7e4425ed/russo2009.pdf. *

Also Published As

Publication number Publication date
CN107260736A (zh) 2017-10-20
EP2533780A1 (en) 2012-12-19
EP2533780A4 (en) 2015-04-08
KR101737388B1 (ko) 2017-05-18
US8980922B2 (en) 2015-03-17
MX2012009211A (es) 2012-09-07
CA2789663A1 (en) 2011-08-18
BR112012020060B8 (pt) 2021-05-25
CA2789663C (en) 2018-10-02
BR112012020060B1 (pt) 2021-05-11
WO2011099305A1 (en) 2011-08-18
JP2013519630A (ja) 2013-05-30
EP2533780B1 (en) 2017-08-23
US20120322826A1 (en) 2012-12-20
JP6023926B2 (ja) 2016-11-09
BR112012020060A2 (pt) 2016-05-10
ES2640752T3 (es) 2017-11-06
CN102753172A (zh) 2012-10-24
KR20130035999A (ko) 2013-04-09
MX343165B (es) 2016-10-26
RU2012139034A (ru) 2014-03-20

Similar Documents

Publication Publication Date Title
RU2569733C2 (ru) Агонисты 5-нт4-рецепторов для лечения деменции
US20230012655A1 (en) Uridine diphosphate derivatives, prodrugs, compositions and uses thereof
TWI465434B (zh) Ｃ５ａＲ拮抗劑
AU2014368961B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JPH0733385B2 (ja) 物質ｐの拮抗薬としてのｎ−アルキルキヌクリジニウム塩
JP2022000421A (ja) τリン酸化を阻害する方法
JP2001506231A (ja) ヘテロ環式チオエステルおよびケトン
JP5576277B2 (ja) グルタミン酸作動性シナプス反応を増大するための二環式アミド
AU2014243707B2 (en) Uridine nucleoside derivatives, compositions and methods of use
KR20140036305A (ko) 유기 화합물
JP2006516559A (ja) ジアリールメチリデンピペリジン誘導体、その製造方法及びその使用
WO2012127878A1 (en) A 5-ht4 receptor agonist as a prokinetic agent
JP7121731B2 (ja) ウリジンヌクレオシド誘導体、組成物及び使用方法
CN100379744C (zh) 抗组胺药快速降低高颅内压的用途
TW202327609A (zh) 治療造血幹細胞移植後的移植物抗宿主病的方法
CA3018115A1 (en) Indolizine derivatives, composition and methods of use
JP2006515352A (ja) 疼痛、不安及び機能的胃腸管障害の治療のためのデルタオピオイド受容体リガンドとしての４−｛［３−（スルホニルアミノ）フェニル］［１−（シクロメチル）ピペリジン−４−イリデン］メチル｝ベンズアミド誘導体
RU2780338C2 (ru) 6-5 КОНДЕНСИРОВАННЫЕ КОЛЬЦА КАК ИНГИБИТОРЫ С5а
WO2024064024A1 (en) ((4-oxo-3,4-dihydroquinazolin-8-yl)methyl)amine derivatives as p13k inhibitors for the treatment of cancer
WO2009085847A1 (en) Tetrahydroindoles having sphingosine-1-phosphate receptor activity

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20170706